Resilient Argenx stock touches fresh all-time high after Forte Biosciences deal
Published on 08/27/2026 at 18:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx SE (ISIN NL0010832176) saw its stock set a new record on August 27, 2026, with the company’s American Depositary Shares hitting an all-time high of $1,059.86 on Nasdaq while it confirmed the completion of its acquisition of Forte Biosciences Inc., adding the FB102 antibody program to its immunology pipeline. An Investing.com company-news report highlights that the Argenx NV ADR stock reached this $1,059.86 milestone on August 27, 2026, marking a new all-time high for the shares.
Record levels and recent price context
The fresh high of $1,059.86 for Argenx ADRs on August 27, 2026, builds on an already elevated trading range that had placed the stock close to its 52-week peak in the preceding sessions. A recent Ad-hoc-news corporate article referenced a quote snapshot showing Argenx stock at $1,012.14 on Nasdaq as of August 24, 2026 at 3:40 p.m. ET, down 2.66 percent in that particular session but still only a few percentage points below a reported 52-week high level of $1,058.69. That earlier price put the shares within a narrow band of their peak, and the subsequent all-time high of $1,059.86 now slightly exceeds that 52-week benchmark.
On the home-market listing in Brussels, Argenx shares have also been trading firmly. Real-time Euronext Brussels data presented by MarketScreener showed the stock at 901.20 EUR in intraday trading on August 27, 2026, representing a gain of 0.40 percent on the day, an increase of 1.81 percent over the preceding five sessions, and a 25.73 percent rise since January 1, 2026. This combination of a new ADR all-time high, solid euro-denominated performance, and year-to-date appreciation underscores the strong investor demand for Argenx shares across venues.
Additional quote context from the US aftermarket highlights the stock’s position within its recent range. A MarketBeat news overview shows Argenx ADRs at $1,058.22 as of 12:21 p.m. ET on August 27, 2026, up 1.06 percent on the session. That intraday reading places the shares almost exactly at the previously reported 52-week high band around $1,058.69 and within a fraction of the $1,059.86 all-time high, emphasizing how tightly the stock is clustered around record territory.
Analyst upgrade and momentum backdrop
The move to new highs comes against a supportive analyst backdrop that has been explicitly positive on Argenx. A Barchart news piece describes how an analyst at UBS upgraded Argenx to a Buy rating and lifted the price target to $1,400 on August 26, 2026, indicating estimated upside of 37 percent from the level used in that analysis. This target, set above both the reported 52-week high of $1,058.69 and the subsequent $1,059.86 all-time high, signals that at least part of the sell-side community expects further appreciation from current prices.
The same MarketScreener overview that recorded 901.20 EUR on Euronext Brussels also lists recent analyst actions, including items noting that UBS moved to a positive stance on Argenx and that this call was accompanied by a share-price reaction. In addition, the news stream for the Nasdaq listing tracked by MarketBeat shows the ADRs reaching $1,058.22 intraday on August 27, 2026, after having traded as high as $1,061.13 in one of the documented sessions, according to the detailed price-alert entry. That high of $1,061.13 is framed as a new 12-month high in the alert and stands slightly above the $1,059.86 all-time high identified by Investing.com, underscoring that the shares are pressing against the top end of their historical range in recent trading.
For investors, the quantified comparison between the analyst target and the current price is striking: with Argenx ADRs circulating around $1,058 to $1,060 on August 27, 2026, the $1,400 target implies a potential gap of approximately $340 per share, or a 37 percent increase, if that view were realized. The euro quote of 901.20 EUR, combined with a 25.73 percent year-to-date increase, highlights that international investors have already seen substantial gains in 2026 even before any further upside that might be implied by bullish research assumptions.
Strategic acquisition of Forte Biosciences and FB102
The share-price strength is occurring alongside a concrete strategic milestone: Argenx’s completion of the acquisition of Forte Biosciences Inc., a transaction that adds the FB102 program to its immunology pipeline. A Business Insider Markets corporate-news item dated August 27, 2026 reports that Argenx announced the successful completion of the Forte takeover, formally turning Forte into a wholly owned subsidiary. The piece explains that the deal was executed via a cash tender offer and subsequent merger.
Additional transaction detail is provided in a separate company-news report. An Investing.com company-news story in Korean notes that the tender offer for Forte Biosciences common stock was conducted at a price of $77.00 per share in cash. At the expiration of the offer, 19,894,879 Forte shares had been tendered, representing 87.13 percent of the company’s outstanding common stock. Following the tender settlement, Argenx completed the acquisition via a merger, bringing the remaining shares under its control and making Forte a wholly owned subsidiary.
This transaction structure means that Argenx likely paid more than $1.53 billion in cash consideration for the tendered Forte shares alone, based on the $77.00 per-share price multiplied by the 19,894,879 shares accepted. The explicit share count and price provide a clear quantitative picture of the deal’s scale. Forte’s lead asset, FB102, is described as an anti-CD122 antibody that now joins the Argenx portfolio, expanding the company’s footprint in targeted immunology therapeutics. The addition of FB102 broadens Argenx’s range beyond its existing platforms and may help support long-term growth expectations that are reflected in the elevated valuation and bullish price targets.
MarketScreener’s French-language note on August 27, 2026 explicitly references Argenx finalizing the acquisition of Forte Biosciences and lists this item alongside other recent news. By pairing an acquisition that delivers a new antibody program with continued momentum in core commercial products such as VYVGART, Argenx is positioning itself as a diversified immunology player with both near-term and pipeline-driven growth levers. The completion of the Forte deal also removes execution risk around the tender offer mechanics and should clarify Argenx’s post-transaction capital structure for investors who track dilution and cash deployment closely.
Earnings context and 2026 performance frame
While the available same-day sources focus more on the price action and corporate transaction than on detailed quarterly numbers, the Ad-hoc-news coverage of August 26, 2026 positions the latest Q2 2026 earnings update as a supporting factor for the stock’s resilience. That article describes how Argenx shares remained close to their 52-week highs following the second-quarter release, highlighting that the market took the numbers and guidance as broadly supportive of the company’s growth narrative. Even though precise revenue and profit figures for Q2 2026 are not reiterated in the present source set, the association between the earnings event and the stock’s tight range around record levels is emphasized.
From a performance standpoint, the Euronext Brussels data showing a 25.73 percent rise year to date as of August 27, 2026 signals that Argenx has materially outperformed many broader indices and sector peers over the course of 2026. If the shares were trading close to 717 EUR at the start of the year, for instance, the move to 901.20 EUR would represent an increase of more than 180 EUR per share, underscoring the magnitude of the rally. The ADR’s climb from levels slightly above $800 earlier in the year to the new high of $1,059.86 similarly illustrates how investors have rewarded Argenx for its clinical and commercial progress.
The quantified comparison between the euro and dollar performances helps investors assess currency-neutral value creation. For example, with a 25.73 percent year-to-date increase in Europe and a corresponding gain in the US that leads to an all-time high just above the 52-week peak, Argenx’s return profile appears consistent across FX exposures. This alignment suggests that the momentum is being driven by fundamental developments rather than purely currency effects, which is relevant for global investors who hold the ADRs but benchmark against euro-based indices.
Pipeline highlight: VYVGART and autoimmune focus
Argenx’s investment case continues to hinge heavily on its innovative immunology portfolio, in particular its FcRn-targeting therapy VYVGART, which has seen regulatory expansion in major markets. The Euronext listing profile notes that the company recently announced US Food and Drug Administration approval expanding VYVGART and VYVGART Hytrulo for use in all adult patients within defined neuromuscular indications, strengthening the commercial footprint of this flagship product. For investors, this means that near-term revenue growth is supported by a broader label and a growing base of treated patients.
VYVGART is designed to reduce pathogenic IgG antibodies by blocking the neonatal Fc receptor, thereby providing a targeted immunomodulatory effect in autoimmune diseases. Its Hytrulo formulation offers a subcutaneous administration option that can be more convenient for some patients compared with intravenous infusion, potentially improving adherence and treatment satisfaction. Combined with the addition of FB102 from the Forte acquisition, Argenx now has a portfolio that spans both commercial-stage therapies and earlier-stage antibody programs, giving it a multi-layered growth profile.
Representative product: VYVGART Hytrulo
VYVGART Hytrulo serves as a representative example of Argenx’s product strategy, blending advanced antibody engineering with patient-friendly delivery. The subcutaneous formulation is designed to be administered in a periodic dosing schedule, offering flexibility and reducing the burden associated with frequent intravenous infusions. In neuromuscular autoimmune conditions, where patients often face chronic weakness and fatigue, the ability to receive an effective therapy outside a traditional infusion center can be a meaningful quality-of-life improvement.
From a business perspective, VYVGART Hytrulo’s expanded US approval supports incremental revenue by opening up treatment to a broader adult population and by providing an option that may increase penetration among patients who prefer or require non-infusion-based care. As more physicians become familiar with the efficacy and safety profile of the Hytrulo formulation, Argenx may see deeper adoption within existing indications, complementing any future label expansions or new disease targets. When read together with the Forte acquisition, this product underscores Argenx’s aim to build a differentiated portfolio of antibody therapies that address both current and emerging immunology needs.
Closing view on Argenx stock and current price levels
As of the most recent documented intraday snapshot on August 27, 2026, Argenx’s Nasdaq-listed ADRs were trading at $1,058.22, up 1.06 percent on the day, according to the MarketBeat news overview, while the shares had set an all-time high of $1,059.86 in trading highlighted by Investing.com. On Euronext Brussels, the stock was quoted at 901.20 EUR with a 0.40 percent daily gain and a 25.73 percent year-to-date increase, based on MarketScreener’s real-time data. These levels place Argenx stock effectively at the top of its historical and 12-month trading ranges, reflecting investor confidence in the company’s immunology franchise, the strengthened pipeline following the Forte Biosciences acquisition, and the supportive analyst backdrop that includes a freshly raised $1,400 price target.
Read more
For additional details on Argenx’s recent corporate developments and investor information, please refer to the company’s investor relations materials on its official website and the latest market data on established financial portals.
Company and stock snapshot
Company: Argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq (ADR) and Euronext Brussels
Price (as of August 27, 2026, 12:21 p.m. ET): $1,058.22 USD
Sector / Industry: Biotechnology - Immunology therapeutics
Index membership: Euronext indices and relevant sector benchmarks
